Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Nov 19, 2019
Latin America ETFs look poised for rallies

Latin America ETFs look poised for rallies

Latin American markets really tumbled in the first half of November and that caused the iShares MSCI Brazil Capped ETF (NYSE: EWZ) and the iShares Latin America 40 ETF (NYSE: ILF) to drop over 5% from November 4 through November 14. Both funds jumped sharply on the 15th and look poised to rally based on a number of different indicators.

First, let's look at the EWZ. We see that the fund has been trending higher since the end of August and a trend channel has formed during this time. The ETF just bounced off of the lower rail of the channel this past week before the bounce on Friday.

The daily stochastic readings are in overbought territory, but they performed a bullish crossover on Friday. The jump also caused the stock to move back above its 50-day moving average, which indicates a change from a downtrend to an uptrend. Accoriding to Tickeron's statistics, in 34 of 39 similar backtested cases where EWZ's price crossed above its 50-day moving average, its price rose further within the subsequent month. The odds of a continued uptrend are 87%.

In addition to the move back above the 50-day, the 50-day just crossed back above its 200-day moving average earlier in November. This indicates a buy signal, due to the trend repositioning higher. In 3 of 3 cases where EWZ's 50-day moving average crossed above its 200-day moving average, its price rose further within the subsequent month. The odds of a continued uptrend are 90%.

Yet another indicator that is pointing to a rally is the Bollinger Bands. The fund fell below the lower Bollinger Band on November 13 and a price increase is expected as the ticker heads toward the middle band. In 40 of 46 cases where EWZ's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued uptrend are 87%.

Turning our attention to the ILF, we see similar patterns and statistics. While the ILF includes stocks outside of Brazil, the fund is heavily populated with Brazilian companies. Like we saw with the EWZ, the ILF has been trending higher since late August and a trend channel has formed. The fund just bounced off the lower rail of the channel and the daily stochastic readings just made a bullish crossover.

The ILF also moved back above its 50-day moving average on November 15 and according to Tickeron's stats, in 42 of 46 cases where ILF's price crossed above its 50-day moving average, its price rose further within the subsequent month. The odds of a continued uptrend are 90%.

The ILF also dropped below its lower Bollinger Band on November 13 and the stats for this fund show increases in the stock price in 36 of 40 cases. The odds of a continued uptrend are 90%.

Obviously there is some overlap between these two funds and they will move in tandem with one another a great deal of time, but they can and will de-couple from time to time. The EWZ has performed a little better over the past year than the ILF, but because the ILF is a little more diversified beyond Brazilian stocks, it tends to be a little less volatile at times.

Related Ticker: EWZ

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


EWZ sees MACD Histogram just turned negative

EWZ saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EWZ as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The 50-day moving average for EWZ moved below the 200-day moving average on August 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EWZ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EWZ broke above its upper Bollinger Band on July 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

EWZ moved above its 50-day moving average on July 20, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for EWZ crossed bullishly above the 50-day moving average on July 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EWZ advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 219 cases where EWZ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Industry description

The investment seeks to track the investment results of the MSCI Brazil 25/50 Index. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization-weighted index designed to measure the performance of the large- and mid- capitalization segments of the equity market in Brazil. The fund is non-diversified.

High and low price notable news

The average weekly price growth across all stocks in the iShares MSCI Brazil ETF ETF was -5%. For the same ETF, the average monthly price growth was -1%, and the average quarterly price growth was -20%. NU experienced the highest price growth at -4%, while XP experienced the biggest fall at -5%.
View a ticker or compare two or three
EWZ
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Unknown

Profile
Details
Category
Focused Region
Address
iShares, Inc.400 Howard StreetSan Francisco
Phone
N/A
Web
www.ishares.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.